Comments of the Board of Statutory Auditors ex 2447 Per saperne di più su Comments of the Board of Statutory Auditors ex 2447
OTOFARMA PRESENTS PRELIMINARY PRO-FORMA CONSOLIDATED RESULTS AS OF DECEMBER 31, 2025: REVENUE UP BY APPROXIMATELY 10% AND STABLE PROFITABILITY, DRIVEN BY A SIGNIFICANT IMPROVEMENT IN EBITDA MARGIN COMPARED TO THE FIRST HALF OF 2025 Per saperne di più su OTOFARMA PRESENTS PRELIMINARY PRO-FORMA CONSOLIDATED RESULTS AS OF DECEMBER 31, 2025: REVENUE UP BY APPROXIMATELY 10% AND STABLE PROFITABILITY, DRIVEN BY A SIGNIFICANT IMPROVEMENT IN EBITDA MARGIN COMPARED TO THE FIRST HALF OF 2025
